Delivery Order SPE2DB22D3016-SPE2DB25FBEG8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,806.98 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes, with an ultimate completion date of September 17, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The contract was executed on September 16, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters....
- The Defense Logistics Agency awarded a $9,158.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Enbrel 50 mg/ml syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a near-term pharmaceutical supply requirement within the military healthcare supply chain. This award is issued under...
- The Defense Logistics Agency awarded a $16,622.35 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Enbrel 50 mg/ml syringes. This firm fixed-price, non-competitive delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 10, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $14.5K delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of ENBREL 25 mg/0.5 ml syringes. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $17,257.88 delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Enbrel 50 mg/ml syringes. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes valued at $68,950.48 on September 12, 2025, with completion targeted for September 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling and extends through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,677.38 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL syringes, with performance in Conshohocken, Pennsylvania and completion targeted for September 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Enbrel 50 mg/mL syringes valued at $23,085.89. This is a firm fixed price delivery order with an ultimate completion date of August 27, 2025, issued with no set-aside designation, indicating competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,030.79 for Enbrel 25 mg/0.5 mL syringes on July 29, 2025, with completion targeted for July 30, 2025. This firm fixed-price contract, with no set-aside designation, represents a competitive award for pharmaceutical supply to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Enbrel 50 mg/mL syringes, valued at $9,158.68 with a firm fixed price structure. The contract has an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBEG8Delivery Order
The Defense Logistics Agency awarded a $29,419.28 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Enbrel 50 mg/ml syringes. The contract, which carries an ultimate completion date of August 8, 2025, represents a non-set-aside, competitively awarded procurement with performance fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The underlying IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates significant experience in fulfilling DLA medical procurement requirements across multiple therapeutic domains, supporting customers including the Defense Health Agency and U.S. Coast Guard. The award of this delivery order underscores the contractor's established capability to meet federal pharmaceutical supply needs through open competition and positions it within DLA's broader strategy to maintain robust pharmaceutical distribution capacity for defense medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.4k | 8/7/25 |